Skip to content

Efficacy and Safety of Enterogermina vs Placebo in Combination with ORT and Zinc for 5 Days Treatment in Children with Acute Diarrhea in India

A randomized, double blind, placebo controlled, parallel group, multicenter, comparative study to assess the efficacy and safety of spores of Enterogermina in combination with oral rehydration therapy (ORT) and Zinc versus placebo in combination with ORT and Zinc administered for 5 days in the treatment of acute diarrhea in children - KIDDIE

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016053
Enrollment
512
Registered
2018-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea Health Condition 2: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Enterogermina®/Bacillus clausii /SSR29263: Enterogermina: 4 billion spores of Enterogermina per day (2 mini bottles per day, one in the morning and one in the evening) for a period of

Sponsors

Sanofi Aventis Groupe
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 6 months less or equal to Age less than or equal to 5 years old 2 Suffering from acute diarrhea of less than 48 hours duration, Diarrhea is defined as unusual loose or watery stools at least 3 times in previous 24 hours period with no signs of dehydration or some dehydration WHO classification 3 Whose parent or legal guardian has given a written informed consent to participate for his or her child in the study at the time of enrollment

Exclusion criteria

Exclusion criteria: 1 Known hypersensitivity to B clausii or any of the excipients or other probiotics 2 Children suffering from chronic GI disease as Crohnâ??s disease, hemorrhagic recto colitis, irritable bowel syndrome, short gut syndrome and inflammatory bowel disease 3 History of or current presence of blood hematochezia, pus, or mucus in stools within the previous 3 months 4 Persistent diarrhea a diarrhea episode which lasts more than 14 days

Design outcomes

Primary

MeasureTime frame
Duration of acute diarrhea (expressed in hours), as counted from the time of randomization up to recovery (the first normal stool as recorded according to Bristol score; a score 5 is described as normalization of stool)Timepoint: Duration of acute diarrhea (expressed in hours), as counted from the time of randomization up to recovery (the first normal stool as recorded according to Bristol score; a score 5 is described as normalization of stool)

Secondary

MeasureTime frame
Safety: adverse event (AEs), including serious adverse event (SAE), adverse event of special interest (AESI) physical examination, and vital signs -Frequency of stool per day - Dehydration status evaluated per WHO classificationTimepoint: 5 days

Countries

India

Contacts

Public ContactMs Salini James

Sanofi-Synthelabo India Private Limited

godhuli.chatterjee@sanofi.com2228032841

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026